Goldman Sachs Upgrades King Pharmaceuticals (KG) to Neutral
Tweet Send to a FriendGet Alerts KG Hot Sheet
Price: $14.24 --0%
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade KG Now!
Goldman Sachs upgrades King Pharmaceuticals, Inc. (NYSE: KG) from Sell to Neutral with a $9.50 price target, implying 14% upside.
The firm said the risk/reward is no more balanced following share decline, the consensus moving down 20%-25%, and risk now better understood.
Downside risks include pipeline failures, weak product trends, and exclusivity losses. Upside risks include improving product trends, strong launches, and M&A potential.
Market Moving News and Intelligence - Free Sign-Up
http://www.streetinsider.com/premium_content.php
The firm said the risk/reward is no more balanced following share decline, the consensus moving down 20%-25%, and risk now better understood.
Downside risks include pipeline failures, weak product trends, and exclusivity losses. Upside risks include improving product trends, strong launches, and M&A potential.
Market Moving News and Intelligence - Free Sign-Up
http://www.streetinsider.com/premium_content.php
You May Also Be Interested In
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- FirstEnergy Capital Upgrades Canadian Natural Resources Limited (CNQ) to Top Pick
- Goldman Sachs Upgrades WNS (Holdings) (WNS) to Buy
Create E-mail Alert Related Categories
Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
